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Most Latin-American countries use subcutaneous immunotherapy (SCIT) extracts from the United States and Europe
and sublingual immunotherapy (SLIT) from Europe, with the exception of Argentina, Brazil, Cuba and Mexico. The
number of researches on immunotherapy (IT) in Latin America has increased extensively in the last years. Only few
Latin American countries have their own guidelines on IT, and, in general, the economic resources for medical
research on IT are still low in the area. A global approach for the future of IT in Latin America includes to improve
standardization, quality control and the production of allergen products, to develop IT guidelines and clinical
investigation by the highest number of countries, to improve the regulatory status for allergens products in the
area, and to expand IT accessibility for low-income patients. In Cuba, the first registered allergen vaccines were
developed and registered in 2006: a standardized (in biologic units) and freeze dried product for SCIT, with a
sublingual version developed in 2009. As much as 23.000 IT treatments were applied in 2011, all provided to
patients free of charge. In 2012, Cuban researchers developed an IT vaccine with adjuvant for subcutaneous route,
which uses Neisseria meningitidis proteoliposome as an adjuvant, added to the purified Dermatophagoides siboney
major allergens: Der s1 and Der s2. Since December 2012, this vaccine is in Phase I clinical trial, evaluating its
safety, tolerability and immunogenicity in asthmatic patients sensitized to this allergen. Cuban perspectives on IT
includes to work on new indications for IT, to investigate the preventive effect and cost-effectiveness for the
current vaccines, to develop new products with mixed formulas of house dust mites for SLIT, to complete the phase
I and II clinical study for dust mite plus adjuvant vaccine, to develop allergen vaccines for fungi allergy and to
complete the Cuban guideline for allergen IT management.
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Allergic diseases represent an economic burden for health
system, both in direct and indirect costs. Allergen-specific
immunotherapy is one of the most important treatments
for allergic disorders, so that the development in this area
can be considered a sensitive indicator regarding the ad-
vances in the management of allergic diseases in a specific
area or country. In addition, allergen-specific immuno-
therapy is currently recognized as a biological response
modifier and the only treatment able to influence the
natural course of allergic disease [1].
Several randomized, placebo-controlled studies and
meta-analysis have confirmed the effectiveness of im-
munotherapy in asthma and rhinitis, with a significant* Correspondence: diaz.alexander38@yahoo.es
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article, unless otherwise stated.reduction in asthma symptoms and medication use, as
well as improvement in bronchial hyper-reactivity [2].
Even more, the U.S. Food and Drug Administration
(FDA) approves the use of subcutaneous allergen ex-
tracts for the treatment of seasonal and perennial aller-
gic rhinitis, allergic asthma, and venom sensitivity and
recently approved the use of sublingual allergen extract
for the treatment of certain grass pollen allergies [3].
Latin America (LA), the region of the Americas where
Romance languages are primarily spoken, includes Mexico,
most of Central and South America and in the Caribbean:
Cuba, the Dominican Republic, and Puerto Rico. It is com-
pounded by 20 countries and has an area of around 20
Million squared kilometers. Its population is estimated at
almost 580 million people, where Brazil, Mexico, Colombia
and Argentina are the most populated countries [4,5].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Cuban ISAAC study 2002- 2004 [26]
Disease 6-7 years 13-14 years
Asthma 31.6% 17.6%
Allergic rhinitis 39.8% 38.5%
Atopic dermatitis 22.3% 14%
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http://www.waojournal.org/content/7/1/28Cuba, officially the Republic of Cuba, is the main
island country in the Caribbean. The island covers an
area of approx. 110. 000 square kilometers and has a
population of over 11 million people, and the climate is
tropical and humid [6].
The purpose of this paper is to describe the present
situation and future perspective of immunotherapy in
Latin America and Cuba.
Review
Latin America
Dermatophagoides pteronissynus, Dermatophagoides farinae,
Blomia tropicalis, Lepidoglyphus and Euroglyphus and are
the most prevalent dust mites in LA [7-10]. Pollens are
also very common in some areas, with a seasonal pattern
in some countries like Argentina and Chile; other import-
ant allergens include cockroach and some airborne fungi
like Alternaria and Aspergillus [11-16].
Sublingual and subcutaneous IT are practiced in all
Latin-American countries, where allergic rhinitis and
asthma are their most common indications [17-19]. IT
for hymenoptera allergy is also common in the area, but
there are few publications about it [20-22]. The majority
of Latin-American countries use SCIT extracts from the
United States and Europe and 50% of them from local
providers. On the other hand, SLIT extracts are mostly
from Europe, but some countries like Argentina, Brazil,
Cuba and Mexico prepare their own SL vaccines. Last,
only a small number of countries fulfill regulatory status
for their allergen products in the area; in this case Brazil,
Cuba and in some extend, Argentina [17,23,24].
The number of studies on immunotherapy (IT) in
Latin America has increased extensively in the last few
years. The publications on adverse events with IT are
beginning to appear. Only few countries have their own
guidelines on IT, and, in general, the economic resources
for medical research on IT are still low in the area [17].
A global approach for the future of IT in LA could be
to improve standardization, quality control and the pro-
duction of Latin American allergen products, to develop
IT guidelines by the highest number of countries and to
encourage clinical investigation on IT. Another import-
ant points comprises the improvement in regulatory sta-
tus for allergens products in the area and the expansion
in IT accessibility for low-income patients.
Cuba
There are 281 allergists in Cuba, with a ration of around
40.000 patients per allergist. Most of the Cuban allergists
belong to the Cuban Society of Allergy, Asthma and
Clinical Immunology, our national affiliation. Currently,
we have 99 allergy services, mostly in primary care.
There are 11 medicine faculties along the country sup-
porting allergy residency, with 94 allergy professors [25].It’s been estimated that, at least, the 20% of the Cuban
population suffer from allergy. Asthma prevalence is also
high, ranging from 9 to 15% in general population. In
children, according to the Cuban ISAAC (International
Study of Asthma and Allergies in Childhood) Study, the
prevalence for asthma, allergic rhinitis and atopic
dermatitis in the ages 6-7 and 13-14 years, ranks high in
the continent (Table 1) [26].
In Cuba, house dust mites are the most important
allergen sources. Blomia tropicalis, Dermatophagoides
pteronyssinus and Dermatophagoides siboney, which is a
variant of Dermatophagoides farinae endemic in Cuba,
are the most significant species [27-31] (Table 2). Some
studies suggest that pollens, cockroaches and fungi could
also be important, but more evidence is necessary to
support it [32-37].
In the nineties, a biotech pole was created in Havana,
and then in other provinces, including important
scientific institutions and industries. All these centers
work together on the application of Biotechnology into
healthcare, developing and manufacturing vaccines and
other biologic products. Cuban biotech pole involve
more than 30 institutions, 15.000 workers, nearly 2.000
researchers and more than 150 research projects. There
is a group of leading centers among them: the Center of
Genetic Engineering and Biotechnology, the Center of
Molecular Immunology and the National Center of Bio-
products (BioCen) [38]. The latter, also called BIOCEN
is the place where the allergen-specific vaccines are
produced at national scale.
To date, three standardized allergenic extracts (Blomia
tropicalis, Dermatophagoides pteronyssinus and Derma-
tophagoides siboney) have been licensed in Cuba for
their use as in-vivo diagnosis and specific immunother-
apy for allergic diseases. These allergen vaccines were
developed and registered in 2006: a standardized (in
biologic units), freeze dried product for SCIT and the
sublingual version was developed in 2009. In 2008, the
vaccines were included into the group of basic medica-
tions by the Cuban Ministry of Health and the SL
variant was incorporated in 2009. In 2011, as much as
23.000 IT treatments were provided to patients free of
charge. About half the total IT vaccines were prescribed
by sublingual route. The potency of Biocen vaccines
were compared with Diater and ALK products with no
statistically significant differences between them [39].
Table 2 Most prevalent allergens in Cuba [27-31]
Most prevalent allergens in Cuba
Dust mites Dermatophagoides pteronyssinus
Dermatophagoides siboney (endemic)
Blomia tropicalis
Pollens Cynodon dactylon (Bermuda grass)
Parthenium hysterophorus (escoba amarga)




Insects Cockroaches (Periplaneta americana)
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an IT vaccine with adjuvant for subcutaneous route
(Figure 1) [40-44]. This new vaccine uses Neisseria
meningitidis proteoliposome, a bacterial product, as an
adjuvant, added to the purified Dermatophagoides siboney
major allergens: Der s1 and Der s2. From December 2012,
this vaccine is in Phase I clinical trial to evaluate safety,
tolerability and immunogenicity in asthmatic patients
sensitized to this allergen. Another vaccine with the same
adjuvant is also being developed with Blomia tropicalis.
There are 11 randomized, controlled clinical trials on
IT (9 already finished), all registered at the Cuban public
registry for clinical trials [45], available at URL: http://
rpcec.sld.cu/en/home. The first clinical trial applied in
children is still in progress: a dose –response study by
SL route. All these trials have used mite vaccines, and
have had asthma as a target. There are also 3 studies on
IT adverse events. Cuban allergists are currently work-
ing on their own guideline for allergen IT management.
Also related, the Cuban Society of Allergology endorsed
and co-organized, with the Cuban Immunology Society,
two international meetings on allergen vaccines in 2009
and 2012.Figure 1 Chronology of development of immunotherapy
in Cuba.Subcutaneous immunotherapy with Blomia tropicalis,
Dermatophagoides pteronyssinus and Dermatophagoides
siboney, the most prevalent Cuban dust mites, has
proved to be effective and safe for the control and ameli-
oration of asthma symptoms in asthmatic patients
[40,42]. The therapeutic effect and safety of Dermato-
phagoides pteronyssinus, Dermatophagoides siboney and
Blomia tropicalis was also demonstrated in asthmatic
patients using SL route. Both clinical symptoms and
medication intake were reduced compared to placebo.
Allergen skin sensitivity also decreased significantly (p <
0.01). PEF (peak expiratory flow) variability also dimin-
ished significantly (p < 0.05). The treatment was consid-
ered effective in 77% of patients. Local reactions were
noted only in 0.43% of administrations and no systemic
reactions were observed [41].
The Cuban perspectives on IT include to work on new
indications for IT, to investigate the preventive effect
and cost-effectiveness for current vaccines, to develop
new products with mixed formulas of house dust mites
for SLIT, to complete the phase I and II clinical study
for dust mite plus adjuvant vaccine, to develop allergen
vaccines for fungi allergy in asthmatics and to complete
the Cuban guideline for allergen IT management.Conclusion
Although most Latin American countries and Cuba are
developing countries, much has been achieved in terms
of treatment and research in immunotherapy, however,
there are still some points requiring improvement in
regard to immunotherapy in the area.
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